CME

----

2026-W382026-09-14

CME.US Weekly Report · 2026-W38

CME’s stock price remained essentially flat this week, surging to 281.36 on Monday before gradually declining, closing at 276.01 on Friday with a gain of just 0.17% versus the prior week’s close. Valuation sits at historically compressed levels but still above industry median, while latest quarterly results showed sequential weakness despite year-over-year gains. Institutional sentiment remains constructive, funds flow remains positive, yet consistent executive share sales present a stark contrast to bullish ratings.

Price Action

During the week (Sept 14-18), the stock opened at 279.78 and closed at 276.01, up 0.17% from the prior Friday’s close of 275.54—essentially flat. Intraweek high of 281.36 (Monday) and low of 269.45 (Wednesday) produced a 4.3% range, indicating search-for-support dynamics.

Average daily volume of 2.14 million shares came in slightly below recent averages with turnover of 0.94%, showing no material volume abnormality. The candle pattern reflects initial strength early week followed by gradual decline, with Wednesday’s bounce failing to reclaim prior peaks—a contracting rally structure indicating consolidation near lows.

Valuation Positioning

Current P/E stands at 23.27x, slightly above the industry median of 19.18x. Valuation snapshot shows P/E of 22.86x at approximately the 12th percentile of the past five years, placing the stock in historical bottom quartile territory. P/B ratio of 3.74x and market cap of approximately $99.2 billion round out the picture.

The percentile positioning indicates sustained structural low valuation rather than temporary dislocation, reflecting underlying fundamental support for the depressed multiple.

Earnings Realization

Latest Q2 2026 results showed mixed momentum. EPS of $2.88 declined 9.4% sequentially from Q1’s $3.18 but rose 2.49% year-over-year from Q2 2025’s $2.81. Operating revenue of $1.70 billion fell 9.3% sequentially though grew 0.81% year-over-year. Net profit of $1.04 billion declined 10.1% sequentially but rose 2.92% year-over-year.

Notable weakness appeared in operating profit, which turned negative year-over-year at -1.97%, signaling emerging cost or expense pressures. Consensus forecast (as of Sept 15) projects annual EPS of $12.41, or roughly $3.10 per quarter, essentially in line with current-quarter results. Q2 performance came in as modestly below expectations rather than materially ahead.

Capital Flows

This week’s capital flows maintained net inflows across all investor tiers. Large institutional net inflow of ~5.91 million, medium institutional of ~4.97 million, and retail of ~1.80 million, combining for total net inflow of ~12.68 million (units unlabeled by source). The composition shows institutional investors driving net inflows at similar magnitude between large and medium tiers, while retail participation remained modest—indicating institution-led accumulation with limited retail follow-through.

Institutional Sentiment

Seventeen institutions cover the name: 3 strong buy, 4 buy, 6 hold for a bullish camp of 13 total; 1 neutral; and 1 reduce/1 sell in the bear camp totaling 2 skeptics. The 76% bullish consensus skews decidedly constructive, though 12% remain cautious.

Latest ratings updated Sept 15 with $283.6 target price, implying ~2.75% upside from current 276.01. Ratings represent backward-looking signals, particularly given that executive selling occurred after ratings publication, creating information asymmetry.

Weekly Newsflow

Key developments this period:

Three principal themes emerge: (1) product expansion continues across leveraged loan index futures, 24/7 silver futures, and single-stock futures, broadening addressable market; (2) infrastructure upgrades with CME Securities Clearing launching December 7 to enhance Treasury market settlement efficiency; (3) management team sustained share sales (CEO executed multiple tranches Aug-Sept totaling several million dollars in aggregate), telegraphing conservative near-term price expectations.

Summary

This week presents a paradox of cheap valuation with institutional support offset by insider pessimism. Valuation metrics paint the bullish case: P/E at 12th percentile versus 5-year history, with 13 of 17 institutions constructive targeting $283.6 (2.75% upside). Capital flows remain positive on institutional buying. Yet management’s sustained selling across at least four news items (CEO and senior legal officer transactions) introduces meaningful share supply that contradicts the bullish consensus, suggesting insiders expect limited near-term appreciation.

Sequential earnings weakness compounds concerns: Q2 results retreated 9-10% from Q1 on most metrics, and operating profit turned negative year-over-year at -1.97%, flagging profitability deterioration. Combined with average daily volume running below trend, the backdrop shows constrained momentum.

In sum, CME trades at depressed valuation amid product-cycle advancement, yet profit deceleration, insider selling, and dampened trading activity form a three-point headwind against near-term appreciation. Forthcoming earnings guidance and management commentary warrant close monitoring to clarify whether insider sales reflect tactical profit-taking or structural conviction shifts.